AI assistant
IMUGENE LIMITED — Investor Presentation 2021
Jun 10, 2021
65124_rns_2021-06-10_c858abcc-965e-419b-a88a-c1218ba105f4.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [116 x 42] intentionally omitted <==
ASX Announcement
Investor Webinar Presentation
__________________________________________________________________________
Sydney, Australia, 11 June 2021: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology , is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held today (Friday, 11th May 2021) from 12:30pm AEST / 10:30am AWST.
Managing Director and CEO, Leslie Chong will provide an overview of the Company’s developing range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.
To access further details of the event and to register at no cost, please copy and paste the
following link into your internet browser:
A recorded copy of the webinar will be made available following the event.
For further information please contact:
Leslie Chong Managing Director and Chief Executive Officer T: +61 458 040 433 E: [email protected]
Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited
IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM [email protected]
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Release authorised by the Managing Director and Chief Executive Officer
2
IMUGENE LIMITED ACN 009 179 551